Analystreport

Sarepta Therapeutics Inc (NASDAQ: SRPT) had its "buy" rating re-affirmed by analysts at Credit Suisse Group AG.

Sarepta Therapeutics, Inc.  (SRPT) 
Last sarepta therapeutics, inc. earnings: 2/26 04:05 pm Check Earnings Report